[01] Ross R. Atherosclerosis-an inflammatory disease.[J] .N Engl J Med. 1999 Jan 14;340(2):115-26. [02] 诸俊仁. 中国成人血脂异常防治指南.[J]. 中华心血管病杂志, 2007, 35(5): 390-419. [03] Sidney C. Smith, Allen J. Taylor, William S. Weintraub, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults. [J].Journal of the American College of Cardiology, 2010, 56(25): 50-103. [04] 中国老年学学会心脑血管病专业委员会,中国医师协会检验医师分会心脑血管病专家委员会中华. 脂蛋白相关磷脂酶A2临床应用专家建议.[J].心血管病杂志 ,2015,43(10):843-846-. [05] Paul S. Jellinger,Donald A. Smith,Adi E. Mehta et al.American Association of Clinical Endocrinologists'' (AACE) Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. [J].Endocrine Practice, 2012,18(1):1-78. [06] Marshall A.Corson, Peter H. Jones, Michael H. Davidson. Review of the Evidence for the Clinical Utility of Lipoprotein-Associated Phospholipase A2 as a Cardiovascular Risk Marker.[J].Am J Cardiol 2008;101[suppl]:41F–50F. [07] Ghosh M, Tucker DE, Burchett SA et al. ProPerties of the GrouP IV Phospholipase A2 family.[J]. Prog Lipid Res, 2006, 45(6): 487-510. [08] Xu RX, Zhang Y, Li XL et al. Relationship between plasma phospholipase A2 concentrations and lipoprotein subfractions in patients with stable coronary artery disease.[J].Clin Chim Acta. 2015,15(446):195-200. [09] 赵永凯,周蕾,黄惠杰,et al. 基于上转换发光技术的生物传感器及其应用.[J].光学学报,2005,25(6):841-847. [10] Emmanouil S. Brilakis, Amit Khera, Darren K. McGuire ,et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: Observations from the Dallas Heart Study. [J].Atherosclerosis,2008, 199:110-115. [11] 宋冬林, 李春华, 王晓东.脂蛋白相关磷脂酶 A2在汉族人群中的分布特点及对冠心病的诊断价值.[J]. 武警医学院学报,2012, 21(4): 241-244. [12] Michelle A. Albert , Robert J. Glynn , Robert L. Wolfert, et,al. The effect of statin therapy on lipoprotein associated phospholipase A2 levels. [J].Atherosclerosis, 2005, 182:193-198. PMID: 15982658. [13] Ridker P M, MacFadyen J G, Wolfert R L, et al. Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.[J]. Clinical chemistry, 2012, 58(5): 877-886. [14] Tsimihodimos V, Kakafika A, Tambaki AP, et al. Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.[J]. J Lipid Res. 2003;44:927-934. [15] John Gregson, Heide A. Stirnadel-Farrant, Indraraj Umesh Doobaree, Carol Koro et al. Variation of lipoprotein associated phospholipase A2 across demographic characteristics and cardiovascular risk factors: A systematic review of the literature.[J]. Atherosclerosis, 2012, 225: 11-21. [16] Thompson A, Gao P, Orfei L, et al. Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies.[J]. Lancet, 2010, 375(9725): 1536-1544. [17] Packard CJ, O’Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med, 2000, 343: 1148-1155. PMID: 11036120. [18] Blake G J, Dada N, Fox J C, et al. A prospective evaluation of lipoprotein-associated phospholipase A2 levels and the risk of future cardiovascular events in women[J]. Journal of the American College of Cardiology, 2001, 38(5): 1302-1306. [19] Ballantyne C M,Hoogeveen R C,Bang H,et al.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.[J]. Circulation, 2004, 109(7): 837-842. [20] Lori B. Daniels,Gail A. Laughlin, Mark J. Sarno, Ricki Bettencourt, Robert L. Wolfert, and Elizabeth Barrett-Connor. Lipoprotein-Associated Phospholipase A2 Is an Independent Predictor of Incident Coronary Heart Disease in an Apparently Healthy Older Population: The Rancho Bernardo Study. [J].J Am Coll Cardiol. 2008, 51(9): 913-919. PMID: 18308160. [21] Marc S. Sabatine, David A. Morrow, Michelle O''Donoghue, et al. Prognostic Utility of Lipoprotein-Associated Phospholipase A2 for Cardiovascular Outcomes in Patients With Stable Coronary Artery Disease. [J].Arterioscler Thromb Vasc Bio, 2007, 27: 2463-2469. [22] Brilakis ES, McCormell JP, Lannon RJ, et a1. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angio-graphic coronary artery disease, and major adverse events at follow-up.[J]. Eur Heart J, 2005, 26: 137-144. [23] Winkler K, Winkelmann BR, Scharnagl H,et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study.[J]. Circulation. 2005.111(8): 980-987. [24] Herrmann J, Mannheim D, Wohlert C, et al. Expression of lipoprotein-associated phospholipase A(2) in carotid artery plaques predicts long-term cardiac outcome [J]. Eur Heart J, 2009, 30(23):2930-2938. [25] 侏雁洲,陈良龙,罗育坤,等.脂蛋白相关磷脂酶 A2 与血管内超声虚拟组织学斑块特征的关系及临床意义.[J].临床心血管病杂志,2010,26(4): 287-290. [26] Gerber Y, McConnell J P, Jaffe A S, et al. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community[J]. Arteriosclerosis, thrombosis, and vascular biology, 2006, 26(11): 2517-2522. PMID: 16902161. [27] O''Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase a2 and its association with cardiovascular outcomes inpatients with acute coronary syndromes in the prove it-timi 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. [J].Circulation. 2006,14(113):1745-1752. [28] Oldgren J, James S K, Siegbahn A, et al. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.[J]. European heart journal, 2007, 28(6): 699-704. [29] Ryu SK, Mallat Z, Benessiano J, Tedgui A, Olsson AG, Bao W, Schwartz GG, Tsimikas S.Phospholipase a2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes. Circulation. 2012,125:757-766. [30] Mitchell S.V. Elkind,Vladimir Leon, Yeseon P. Moon,et al. High-Sensitivity C-Reactive Protein and Lipoprotein-Associated Phospholipase A2 Stability Before and After Stroke and Myocardial Infarction. [J].Stroke. 2009, 40: 3233-3237. [31] Jabor B, Choi H, Ruel I, et al. Lipoprotein-Associated Phospholipase A 2 (Lp-PLA 2) in Acute Coronary Syndrome: Relationship With Low-Density Lipoprotein Cholesterol.[J]. Canadian Journal of Cardiology, 2013, 29(12): 1679-1686. [32] Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. [J].Circulation, 2005, 111: 570-575. [33] Caslake M J, Packard C J, Robertson M, et al. Lipoprotein-associated phospholipase A 2, inflammatory biomarkers, and risk of cardiovascular disease in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).[J]. Atherosclerosis, 2010, 210(1): 28-34. [34] hasan Kara, Murat Aakinci,selim Degirmenci,et al. high-sensitivity C-reactive protein, lipoprotein-related phospholipase A2, and acute ischemic stroke.[J].Neuropsychiatric Disease and Treatment, 2014,10:1451-1457. [35] Cucchiara BL, Messe SR, Sansing L, MacKenzie L, Taylor RA, Pacelli J, Shah Q, Kasner SE. Lipoprotein-associated phospholipase a2 and c-reactive protein for risk-stratification of patientswith tia. [J].Stroke. 2009;40:2332-2336. [36] Delgado P, Chacon P, Penalba A, Pelegri D, Garcia-Berrocoso T, Giralt D, Santamarina E, Ribo M, Maisterra O, Alvarez-Sabin J, Rosell A, Montaner J. Lipoprotein-associated phospholipase a(2) activity is associated with large-artery atherosclerotic etiology and recurrent stroke in tia patients.[J].Cerebrovasc Dis. 2012;33:150-158. [37] Mitchell S. V. Elkind, Wanling Tai, Kristen Coates, ,et al. High-Sensitivity C-Reactive Protein, Lipoprotein-Associated Phospholipase A2, and Outcome After Ischemic Stroke.[J].Arch Intern Med. 2006, 166: 2073-2080. [38] White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. [J].N Engl J Med,2014;370:1702–11. [39] USED R. Lipid-related markers and cardiovascular disease prediction.[J].JAMA,2012,307(23): 2499-2506. [40] Andrus B, Lacaille D. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk.[J]. J Am Coll Cardiol, 2014, 63(25_PA): 2886-2886. [41] 2010 AHA/ASA Guidelines for the Primary Prevention of Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. [J].Stroke , 2011, 42: 517-584. [42] Joep Perk,Guy De Backer,Helmut Gohlke,et al.European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012).[J]. Int J Behav Med, 2012, 19(4): 403-488. [43] Ballantyne CM,Hoogeveen RC, Bang H, et al.Lipoprotein-associated phospholipase A2 , high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Commu-nities (ARIC) study. [J].Arch Intern Med 2005;165:2479–84. [44] O’Donoghue ML, Braunwald E, White HD, et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. [J].JAMA 2014;312:1006–15.
|